Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis to buy Auden Mckenzie for GBP306m
Auden Mckenzie will be acquired on a debt free basis, and the transaction will exclude Auden Mckenzie’s real estate portfolio. The acquisition will make Actavis the number one
Auden Mckenzie will be acquired on a debt free basis, and the transaction will exclude Auden Mckenzie’s real estate portfolio. The acquisition will make Actavis the number one
The agreement establishes the collaboration and structure to enable better scientific understanding of the medicinal use of cannabis to treat diseases such as Parkinson’s, epilepsy, Alzheimer’s, brain damage,
The expanded agreements will allow Gilead’s India-based partners to manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries, which together
Ajinomoto Pharmaceuticals holds the manufacturing and marketing authorization rights to LIVAMIN Oral Granules. Under a basic contract concerning the marketing rights of LIVAMIN Oral Granules in the Asia
The Fast Track designation process of the FDA is designed to facilitate the development and expedite the review and approval of drugs intended to treat serious or life
"Retinal vein occlusion is a common retinal vascular disorder with an estimated 16.4 million people affected worldwide, and it is a severe disease which is potentially blinding if
Bexsero is the only meningitis B vaccine approved in the US with a two-dose regimen and a flexible dosing schedule[1]. As part of the accelerated approval process, Novartis
If approved in the EU, ruxolitinib could provide the first targeted treatment option for these patients. PV is a chronic, incurable blood cancer associated with an overproduction of
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH. Natpara, a bioengineered replica of human PTH, is expected to be available in
The OS results in 123 patients demonstrated that aldoxorubicin-treated patients demonstrated a 27 percent reduction in the risk of death compared to patients treated with doxorubicin (HR 0.73: